Adimab partners with Boehringer Ingelheim to optimize antibodies against targets
Adimab partners with Boehringer Ingelheim to discover and optimize antibodies against targets selected by BI who exclusively possesses the right to develop and commercialize therapeutic…
Read More...
Read More...